rAAV4E-Des520-alpha-sarcoglycan

rAAV4E-Des520-alpha-sarcoglycan is an experimental gene therapy designed for the treatment of limb-girdle muscular dystrophy type 2D (LGMD2D), also known as sarcoglycanopathy R3. LGMD2D is a rare autosomal recessive neuromuscular disorder caused by mutations in the SGCA gene, which leads to a deficiency in the alpha-sarcoglycan protein and subsequent destabilization of the sarcoglycan complex at the sarcolemma. This therapeutic candidate utilizes a recombinant adeno-associated virus (rAAV) vector with an engineered muscle-tropic capsid (rAAV4E) and an optimized muscle-specific promoter (Des520) to drive high-level expression of the human alpha-sarcoglycan transgene in skeletal and cardiac muscle. By restoring alpha-sarcoglycan levels and ensuring its proper sarcolemmal localization, the therapy aims to stabilize the dystrophin-associated glycoprotein complex and prevent progressive muscle wasting. Preclinical studies in SGCA-deficient mouse models have demonstrated dose-dependent protein restoration and histopathological improvement in both skeletal and cardiac muscle tissues.